All the news Showing 6 of 6 articles from: Treatment and HCV genotypeGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir/velpatasvir is suitable for treatment of genotype 4 variants in Africa Keith Alcorn / 12 April 2022 Sofosbuvir/velpatasvir is safe and effective for the treatment of hepatitis C genotype 4 variants that have naturally occurring resistance to some direct-acting antivirals in the NS5A inhibitor class, a study in Rwanda has ... Maviret cures most people with HCV genotype 3 and those with cirrhosis Liz Highleyman / 24 October 2017 Glecaprevir and pibrentasvir, the two drugs in the recently approved Maviret co-formulation, demonstrated high sustained response rates for people with chronic hepatitis C virus (HCV) genotype 3 and for people with liver ... EASL issues new hepatitis C treatment recommendations for all genotypes Liz Highleyman / 26 September 2016 The European Association for the Study of the Liver (EASL) released its latest recommendations on treatment of hepatitis C at a special meeting last Thursday in Paris. The updated guidelines now include highly ... Sofosbuvir/ledipasvir is safe and effective for relapsers and hard-to-treat patients Liz Highleyman / 11 April 2014 A co-formulation of sofosbuvir and ledipasvir successfully treated a variety of difficult-to-treat patient populations including people with hepatitis C virus (HCV) genotype 3, people with decompensated cirrhosis and people who were not cured ... US medical societies launch new hepatitis C treatment guidelines Liz Highleyman / 30 January 2014 The American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA) and International Antiviral Society-USA (IAS-USA) yesterday announced the first new hepatitis C treatment guidelines ... Sofosbuvir/ribavirin for 24 weeks cures most genotype 3 hepatitis C patients, adding interferon may help difficult-to-treat Liz Highleyman / 14 November 2013 A dual oral regimen of sofosbuvir plus ribavirin led to sustained response for 93% of people with genotype 2 hepatitis C treated for 12 weeks and 85% of people with genotype 3 ... ← First1Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive